摘要
目的:探讨消化道肿瘤患者化疗相关性腹泻的治疗方法。方法:62例化疗相关性腹泻患者随机分成3组,A组口服洛哌丁胺,B组皮下注射奥曲肽,C组皮下注射奥曲肽的同时口服培菲康。观察患者治疗前后的KPS评分和腹泻的治疗效果并进行统计学分析。结果:A组患者治疗前后KPS评分无显著性差异,B组和C组治疗后KPS评分明显高于治疗前。治疗后B组KPS评分高于A组低于C组。B组的腹泻治疗效果与A组和C组都有明显差异。结论:奥曲肽对化疗相关性腹泻有较好治疗效果,奥曲肽和培菲康共同应用的治疗效果更加明显。
Objective： To explore the therapeutic regimen for chemotherapy - induced diarrhea （CID） in patients with digestive tract carcinoma. Methods： Sixty - two patients with CID were divided into three groups randomly. Group A took loperamide orally, Group B was subcutaneously injected octreotide. Group C was subcutaneously injected octreotide and administered Birid Triple Viable （BIFICO） simultaneously. The Karnofsky performance status （KPS） score was recorded and the therapeutic outcome was observed, Results： There was no significant difference in KPS score for group A before and after therapy. The KPS score was significantly higher in Group B and Group C after therapy, The KPS score for Group B was higher than that in Group A and lower than that in Group C, The therapeutic outcome of Group B was significantly different with Group A and group C. Conclusion： Octreotide has better efficacy in the treatment of CID, Combination therapy with octreotide and BIFICO mag achieve more apparent outcome,
出处
《上海医药》
CAS
2007年第11期523-525,共3页
Shanghai Medical & Pharmaceutical Journal
关键词
化疗相关性腹泻
洛哌丁胺
奥曲肽
培菲康
chemotherapy - induced diarrhea
loperamide
octreotide
Birid Triple Viable （BIFICO）
